DOI: https://dx.doi.org/10.18203/2349-3933.ijam20222609
Published: 2022-10-26

Real-world use and acceptance of biosimilar rituximab in oncology practice in India

Deepak Bunger, Anil Rajani, Lav Patel, Shreekant Sharma

Abstract


Background: To describe the treatment patterns, patient characteristics and usage pattern of biosimilar rituximab for the treatment of Non-Hodgkin lymphomas (NHL) in India.

Methods: This real-world, retrospective, analysis included adult patients receiving biosimilar rituximab between April 2021 and March 2022.

Results: A total of 750 patients with NHL who received biosimilar rituximab were included. The most common indications reported in this analysis were diffuse large cell B-cell lymphoma [DLBCL, 64.5% (n=484)], follicular lymphoma, [FL, 23.7% (n=178)], and mantle cell lymphoma [MCL, 5.3% (n=40)]; other subtypes constituted 6.4% of the patients (n=48). The mean age of patients among DLBCL, FL and MCL was 65.5, 55.3 and 57 years, respectively. Across the lymphomas, >90% of the patients received R-chemo as first-line therapy. R-CHOP was the most common regimen across indications.

Conclusions: Biosimilar rituximab-based chemotherapy is being adopted in real‑world clinical practice in India for the management of patients with B-cell NHL including DLBCL, FL, MCL and other lymphomas.


Keywords


Rituximab, Biosimilar, Lymphoma, Non-Hodgkin

Full Text:

PDF

References


Boffetta PI. Epidemiology of adult non-Hodgkin lymphoma. Ann Oncol. 2011;22:iv27-31.

Hallek M. Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment. Am J Hematol. 2015;90:446-60.

Hill M, Kyle F. NHL (diffuse large B-cell lymphoma). BMJ Clin Evidence. 2010;2010.

International Agency for Research on Cancer, World Health Organization. GLOBOCAN 2018: estimated cancer incidence, mortality and prevalence worldwide in 2018. World fact sheet. 2018. Available at: https://gco.iarc.fr/today/data/factsheets/populations/900-world-fact-sheets.pdf. Accessed on 26 June, 2022.

Fisher SG, Fisher RI. The epidemiology of non-Hodgkin's lymphoma. Oncogene. 2004;23:6524-34.

Cancer Research UK. Non-Hodgkin lymphoma (C82-C86): 1979-2013 European age-standardised incidence rates per 100,000 population, by sex, Great Britain. 2013. Available at: http://www.cancerresearchuk.org/sites/default/files/cstream-node/inc_asr_gb_nhl_1.pdf. Accessed on 26 June, 2022.

National Cancer Institute. Surveillance, Epidemiology, and End Results Program. Cancer Stat Facts: Non-Hodgkin Lymphoma. 2017. Available at: http://seer.cancer.gov/statfacts/html/nhl.html. Accessed on 26 June, 2022.

Nair R, Arora N, Mallath MK. Epidemiology of Non-Hodgkin's Lymphoma in India. Oncology. 2016;91(1):18-25.

Dotan E, Aggarwal C, Smith MR. Impact of Rituximab (Rituxan) on the Treatment of B-Cell Non-Hodgkin's Lymphoma. J Formulary Management. 2010;35:148-57.

Plosker GL, Figgitt DP. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs. 2003;63:803-43.

FDA. ‘Biosimilar and interchangeable products’. 2017. Available at: www.fda.gov/drugs/biosimilars/biosimilar-and-interchangeable-products. Accessed on 26 June, 2022.

FDA. ‘Biosimilars’. 2020. Available at: www.fda.gov/drugs/therapeutic-biologics-applications-bla/biosimilars. Accessed on 26 June, 2022.

Calvo B, Zuñiga L. The US approach to biosimilars: the long-awaited FDA approval pathway. BioDrugs: Clin Immunotherap Biopharma Gene Therapy. 2012;26:357-61.

Shelbaya A, Kelton JM, Thompson J, Alvir JM, Maculaitis MC, Yang J. Real-world use and acceptance of biosimilar monoclonal antibodies of rituximab in oncology practice in the USA. Future Oncol (London, England). 2021;17:3941-50.

Nimmagadda RB, Digumarti R, Nair R, Bhurani D, Raina V, Aggarwal S et al. Histopathological pattern of lymphomas and clinical presentation and outcomes of diffuse large B cell lymphoma: A multicenter registry based study from India. Ind J Med Paediatr Oncol. 2013;34:299-304.

Gogia A, Das CK, Kumar L, Sharma A, Tiwari A, Sharma MC et al. Diffuse large B-cell lymphoma: An institutional analysis. South Asian J Cancer. 2018;7:200-02.

Coiffier B, Sarkozy C. Diffuse large B-cell lymphoma: R-CHOP failure-what to do? Hematol Am Soci Hematol Educat Program. 2016;2016:366-78.

Stegemann M, Denker S, Schmitt CA. DLBCL 1L-What to Expect beyond R-CHOP? Cancers. 2022;14.

Gogia A, Raina V, Kumar L, Sharma A, Sharma M, Mallick SR. Follicular lymphoma: an Institutional Analysis. Asian Pacific J Cancer Prevention. 2017;18:681-5.

Wu JQ, Song YP, Su LP, Zhang MZ, Li W, Hu Y et al. Three-year Follow-up on the Safety and Effectiveness of Rituximab Plus Chemotherapy as First-Line Treatment of Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in Real-World Clinical Settings in China: A Prospective, Multicenter, Noninterventional Study. Chin Med J. 2018;131:1767-75.

Das Ch K, Gogia A, Kumar L, Sharma A, Sharma M, Mallick SR. Mantle Cell Lymphoma: A North Indian Tertiary Care Centre Experience. Asian Pacific J Cancer Prevention. 2016;17:4583-6.

Norbeck TB. Drivers of health care costs. A Physicians Foundation white paper-second of a three-part series. Missouri Med. 2013;110:113-8.

Dinesh TA, Nair P, Abhijath V, Jha V, Aarthy K. Economics of cancer care: A community-based cross-sectional study in Kerala, India. South Asian J Cancer. 2020;9:7-12.

Cortes J, Perez-García JM, Llombart-Cussac A, Curigliano G, El Saghir NS, Cardoso F et al. Enhancing global access to cancer medicines. CA Cancer J Clin. 2020;70:105-24.

Dolan C. Opportunities and challenges in biosimilar uptake in oncology. Am J Managed Care. 2018;24:S237-43.

Lyman GH, Zon R, Harvey RD, Schilsky RL. Rationale, Opportunities, and Reality of Biosimilar Medications. N Eng J Med. 2018;378:2036-44.